Experimental study on the efficacy of combination of α-helical antimicrobial peptides and vancomycin against Staphylococcus aureus with intermediate resistance to glycopeptides

Peptides

Volumn 27, Issue 11, 2006, Pages 2600-2606

  Cirioni, Oscar ^a   Silvestri, Carmela ^a   Ghiselli, Roberto ^a   Giacometti, Andrea ^a   Orlando, Fiorenza ^b   Mocchegiani, Federico ^a   Chiodi, Leonardo ^a   Vittoria, Agnese Della ^a   Saba, Vittorio ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

Antimicrobial peptides; Glycopeptides; Staphylococcal sepsis; Staphylococci

Indexed keywords

CECROPIN A; GLYCOPEPTIDE; INTERLEUKIN 6; MAGAININ 2; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BLOOD CULTURE; CONTROLLED STUDY; DRUG EFFICACY; LETHALITY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RAT; SEPSIS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GLYCOPEPTIDES; MALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PROTEIN STRUCTURE, SECONDARY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 33750041999     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.05.004     Document Type: Article

References (32)

1. Cannon M. Antimicrobial peptides. A family of wound healers. Nature 328 (1987) 478
2. Clinical and Laboratory Standards Institute (CLSI) 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard M7-A6. Villanova, PA.
3. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility test, approved standard M2-A7. 7th ed. (2003), National Committee for Clinical Laboratory Standards, Wayne, PA
4. Eliopoulos G.M., and Moellering Jr. R.C. Antimicrobial combinations. In: Lorian V. (Ed). Antibiotics in laboratory medicine (1996), Williams & Wilkins, Baltimore, MD 330-393
5. Geisel R., Schmitz F.J., Thomas L., Berns G., Zetsche O., Ulrich B., et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J Antimicrob Chemother 43 (1999) 846-848
6. Giacometti A., Cirioni O., Barchiesi F., Del Prete M.S., and Scalise G. Antimicrobial activity of polycationic peptides. Peptides 20 (1999) 1265-1273
7. Giacometti A., Cirioni O., Ghiselli R., Orlando F., Mocchegiani F., Riva A., et al. Efficacy of quinupristin/dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides. Antimicrob Agents Chemother 46 (2002) 2885-2888
8. Giacometti A., Cirioni O., Kamysz W., D'Amato G., Silvestri C., Del Prete M.S., et al. In-vitro activity of histatins derivative P-113 alone and in combination with antimicrobial agents against multidrug-resistant pathogens responsible of pneumonia in immunocompromised patients. Antimicrob Agents Chemother 49 (2005) 1249-1252
9. Hancock R.E.W., and Chapple D.S. Peptide antibiotics. Antimicrob Agents Chemother 43 (1999) 1317-1323
10. Hancock R.E.W., and Scott M.G. The role of antimicrobial peptides in animal defences. Proc Natl Acad Sci USA 97 (2000) 856-861
11. Hindler J. Tests to assess bactericidal activity. In: Eisenberg H.D. (Ed). Clinical microbiology procedures handbook (1992), American Society for Microbiology, Washington, DC 5.16.14-5.16.24
12. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
13. Hultmark D., Steiner H., Rasmuson T., and Boman H.G. Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur J Biochem 106 (1980) 7-16
14. Huttner K.M., and Bevins C.L. Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res 45 (1999) 785-794
15. Lowy F.D. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 111 (2003) 1265-1273
16. Luders T., Birkemo G.A., Fimland G., Nisser-Meyer J., and Nes I.F. Strong synergy between a eukaryotic antimicrobial peptide and bacteriocins from lactic acid bacteria. Appl Environ Microbiol 69 (2003) 1797-1799
17. Moore A.J., Beazley W.D., Bibby M.C., and Devine D.A. Antimicrobial activity of cecropins. J Antimicrob Chemother 37 (1996) 1077-1089
18. Moore M.R., Perdreau-Remington F., and Chambers H.F. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 47 (2003) 1262-1266
19. Noskin G.A., Siddiqui F., Stosor D., Hacek D., and Peterson L.R. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 43 (1999) 2059-2062
20. Reddy K.V.R., Yedery R.D., and Aranha C. Antimicrobial peptides: premises and promises. Int J Antimicrob Agents 24 (2004) 536-547
21. Rotun S.S., McMath V., Schoonmaker D.J., Maupin P.S., Tenover F.C., Hill B.C., et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteraemia. Emerg Infect Dis 5 (1999) 147-149
22. Sanyal D., Johnson A.P., George R.C., Cookson B.D., and Williams A.J. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet 337 (1991) 54
23. Scott M.G., Yan H., and Hancock R.E.W. Biological properties of structurally related α-helical cationic antimicrobial peptides. Infect Immun 67 (1999) 2005-2009
24. Shin S.Y., Yang S.T., Park E.J., Eom S.H., Song W.K., Kim Y., et al. Salt resistance and synergistic effect with vancomycin of α-helical antimicrobial peptide P18. Biochem Biophys Res Commun 290 (2002) 558-562
25. Sieradzki K., and Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of S. aureus. J Bacteriol 179 (1997) 2557-2566
26. Sieradzki K., Villari P., and Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 42 (1998) 100-107
27. Tenover F.C. Implications of vancomycin resistant Staphylococcus aureus. J Hosp Infect 43 (1999) S3-S7
28. Wade D., Boman A., Wåhlin B., Drain C.M., Andreu D., Boman H.G., et al. All-D amino acid-containing channel-forming antibiotic peptides. Proc Natl Acad Sci USA 87 (1990) 4761-4765
29. Woodford N., Johnson A.P., Morrison D., and Speller D.C.E. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 8 (1995) 585-615
30. Yan H., and Hancock R.E. Synergistic interaction between mammalian antimicrobial defense peptides. Antimicrob Agents Chemother 45 (2001) 1558-1560
31. Zarrouk V., Bozdogan B., Leclercq R., Garry L., Feger C., Carbon C., et al. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. Antimicrob Agents Chemother 45 (2001) 1244-1248
32. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 84 (1987) 5449-5453